Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) is engaged within the research, development, and commercialization of cannabis-based pharmaceuticals to treat a wide range of ailments. Shares of the cannabis pharmaceutical developer are rallying 17.89%, through early trading on Tuesday, November 28, 2017. Over the past month, Cannabics Pharmaceuticals, Inc. has seen average daily volume of 274,162 shares. However, volume of 685,563 shares or dollar volume of $774,686, has already exchanged hands on the day.
Shares of Cannabics Pharmaceuticals, Inc. are rallying today, after the company announced that it has received a new license from the Israeli Ministry of Health to test CBD compounds within the treatment of tumors. The research license gives the company a wide range of capabilities to begin testing and research. Here is the full press release detailing of the research license:
Cannabics Pharmaceuticals, Inc. Press Release:
TEL-AVIV, Israel, Nov. 28, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids.
The new license will enable the company to continue our vision of developing an ecosystem for creation of diagnostic tools and bringing to the market diagnostic services for cancer patients who are medicated with cannabis. Our forward looking plan encompasses a synergy between HTS (High Throughput Screening), CTCs (Circulating Tumor Cells), Drug Efficacy, and Genomic Data to provide therapists and their patients with personalized supportive data for their treatment.
About Cannabics Pharmaceuticals, Inc.
Cannabics Pharmaceuticals, Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 17th, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.